GSK's Blenrep (belantamab mafodotin) has officially been approved by the UK's Medicines and Healthcare products Regulatory ...

LONDON, UK I April 17, 2025 I GSK plc (LSE/NYSE: GSK) today announced the authorisation of Blenrep by the Medicines and Healthcare products Regulatory Agency ...

UK pharma major GSK on Friday announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has licensed Blenrep (belantamab mafodotin) in combinations with bortezomib plus ...

GSK said on Thursday two combination therapies with its cancer drug, Blenrep, have received approval from British authorities ...

The London-based pharmaceutical company said Blenrep, or belantamab mafodotin, was approved for the treatment of adult patients with multiple myeloma in combination with bortezomib plus dexamethasone, ...

Hesham Abdullah, global head of oncology R&D at GSK, said the results “reinforce our belief in the potential for belantamab mafodotin used in combination to redefine the treatment of multiple ...

In spring 2021, my family sold a big lump of GSK shares. Four years later, we have no regrets. Indeed, with the GSK share price stumbling, we may buy soon. When investing, your capital is at risk.

PHILADELPHIA, April 09, 2025--GSK awards $2M in grant funding for programs supporting adult vaccination, commits additional $2M for 2025 ViiV Healthcare, the global specialist HIV company majority ...

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together. The Company is ...